• Publications
  • Influence
Functional annotation of rare gene aberration drivers of pancreatic cancer
As we enter the era of precision medicine, characterization of cancer genomes will directly influence therapeutic decisions in the clinic. Here we describe a platform enabling functionalization ofExpand
  • 40
  • 3
RET fusion as a novel driver of medullary thyroid carcinoma.
INTRODUCTION Oncogenic RET tyrosine kinase gene fusions and activating mutations have recently been identified in lung cancers, prompting initiation of targeted therapy trials in this disease.Expand
  • 41
  • 2
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
KRAS, an oncogene mutated in nearly one third of human cancers, remains a pharmacologic challenge for direct inhibition except for recent advances in selective inhibitors targeting the G12C variant.Expand
  • 7
  • 1
Systematic Functional Annotation of Somatic Mutations in Cancer.
The functional impact of the vast majority of cancer somatic mutations remains unknown, representing a critical knowledge gap for implementing precision oncology. Here, we report the development of aExpand
  • 73
Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.
Oncogenic gene fusions drive many human cancers, but tools to more quickly unravel their functional contributions are needed. Here we describe methodology permitting fusion gene construction forExpand
  • 16
Analyzing Somatic Genome Rearrangements in Human Cancers by Using Whole-Exome Sequencing.
Although exome sequencing data are generated primarily to detect single-nucleotide variants and indels, they can also be used to identify a subset of genomic rearrangements whose breakpoints areExpand
  • 24
  • PDF
SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
FGFR1 was recently shown to be activated as part of a compensatory response to prolonged treatment with the MEK inhibitor trametinib in several KRAS-mutant lung and pancreatic cancer cell lines. WeExpand
  • 17
In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer
Genetic aberrations driving pro-oncogenic and pro-metastatic activity remain an elusive target in the quest of precision oncology. To identify such drivers, we use an animal model of KRAS-mutant lungExpand
  • 7
Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression
The melanoma-associated antigen family A (MAGEA) antigens are expressed in a wide variety of malignant tumors but not in adult somatic cells, rendering them attractive targets for cancerExpand
  • 1